Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study

H. S. Hochster(Sarah Cannon), Barrett H. Childs(Florida Hospital Cancer Institute), Eric Hedrick(Florida Hospital Cancer Institute), John D. Hainsworth(Sarah Cannon), Lowell L. Hart(Florida Cancer Specialists & Research Institute), Ramesh K. Ramanathan(Ironwood Pharmaceuticals (United States))
Journal of Clinical Oncology
June 20, 2006
10.1200/jco.2006.24.18_suppl.3510
Cited by 137

Related Papers

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
|Journal of Clinical Oncology|2008|695
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623